72.19.Z - Scientific research and development activities
20.59.Z - Manufacture of other chemical products, not elsewhere classified
21.10.Z - Manufacture of basic pharmaceutical products
21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
46.75.Z - Wholesale trade
58.11.Z - Publishing of books
71.20.B - Inspection and issuing opinions on the technical condition of chimneys and ventilation ducts
72.11.Z - Scientific research and development activities
74.90.Z - Other professional, scientific and technical activities, not elsewhere classified
77.40.Z - Leasing of intellectual property and similar products, excluding works protected by copyright
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | 5,7 | 1,6 | 2,5 | 54,2 |
EBITDA | 3,5 | 3,2 | 3,6 | 14,8 |
Short time liabilities | 10,3 | 11,2 | 11,5 | 2,4 |
Equity capital | 72,3 | 74 | 75,2 | 1,6 |
Operating profit (EBIT) | 1,5 | 1,4 | 2,3 | 68,4 |
Assets | 112,9 | 113 | 115,1 | 1,8 |
Net profit (loss) | 5,6 | 1,5 | 2,4 | 56,4 |
Cash | 43,3 | 44,8 | 39 | -13 |
Liabilities and provisions for liabilities | 40,6 | 39,1 | 39,9 | 2,2 |
Net income from sale | 44 | 42,3 | 43,7 | 3,5 |
Working assets | 53,8 | 54,2 | 57,4 | 5,8 |
Depreciation | 2 | 1,8 | 1,3 | -26 |
% | % | % | p.p. | |
Profitability of capital | 7,7 | 2,1 | 3,2 | 1,1 |
Equity capital to total assets | 64 | 65,4 | 65,3 | -0,1 |
Gross profit margin | 12,8 | 3,9 | 5,7 | 1,8 |
EBITDA Margin | 8 | 7,5 | 8,3 | 0,8 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 86 | 97 | 96 | -1 |
Current financial liquidity indicator | 1.5549665689468384 | 1.6263948678970337 | 1.6799434423446655 | 0,1 |
Net dept to EBITDA | -11.763449668884277 | -13.731616973876953 | -10.328330039978027 | 3,4 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane